Osteoporosis Treatment Gap
Quick Facts
Who should be screened for osteoporosis?
Osteoporosis is a condition of low bone mass and deteriorated bone structure that raises fracture risk. It is usually silent until a fracture occurs, often of the hip, spine, or wrist. The USPSTF recommends screening with bone density testing for women aged 65 and older, and for postmenopausal women younger than 65 whose risk is elevated, as assessed by a clinical risk tool. Evidence is less certain for routine screening in men, though many guidelines advise testing men with risk factors.
Risk factors include prior fracture, family history of hip fracture, low body weight, smoking, heavy alcohol use, and long-term use of glucocorticoids. Dual-energy X-ray absorptiometry (DXA) is the standard test, and tools such as FRAX estimate 10-year fracture probability by combining bone density with clinical factors.
How do osteoporosis drugs reduce fracture risk?
Bisphosphonates such as alendronate and zoledronic acid are commonly used first-line treatments and reduce bone resorption by osteoclasts. Denosumab, an antibody against RANKL, also limits bone breakdown, but stopping it without follow-up therapy can lead to rapid bone loss, so planning is important. Anabolic agents, including teriparatide, abaloparatide, and romosozumab, build bone and are often considered for people at very high fracture risk. Choice depends on fracture risk, kidney function, other conditions, and patient preference.
These drugs have rare but recognized adverse effects, such as osteonecrosis of the jaw and atypical femur fractures, particularly with long-term use. For most people at high risk, the fracture-prevention benefit outweighs these risks. Calcium and vitamin D adequacy, weight-bearing and resistance exercise, fall prevention, and avoiding smoking are important complements to medication.
Why does the treatment gap persist, and what is the brain-health angle?
A major missed opportunity is after a first fragility fracture. Many patients have the fracture repaired but are not tested or started on therapy, even though a prior fracture is among the strongest predictors of another. Fracture liaison services, which systematically identify and follow such patients, have been promoted by bone health organizations to close this gap. Concerns about rare side effects and low awareness among patients and clinicians also contribute.
Recent large studies reported by ScienceDaily, including an analysis of more than 120,000 older adults, found that people using common osteoporosis drugs had up to 24% lower dementia risk. These observational findings need confirmation in randomized trials and should not change prescribing. They do, however, highlight that bone health and aging are closely linked, and that visiting a clinician about bone density is worthwhile for the fracture protection alone.
Frequently Asked Questions
The USPSTF recommends screening for women 65 and older, and earlier for postmenopausal women at elevated fracture risk, based on clinician assessment.
They are effective and generally well tolerated, though rare side effects such as osteonecrosis of the jaw and atypical femur fractures can occur. Your doctor can weigh the risks and benefits for you.
Exercise, adequate calcium and vitamin D, and not smoking help support bone health, but people at high fracture risk often need medication as well.
References
- U.S. Preventive Services Task Force. Screening for Osteoporosis to Prevent Fractures: Recommendation Statement. JAMA. 2018.
- National Institutes of Health, Osteoporosis and Related Bone Diseases National Resource Center. Osteoporosis overview.
- ScienceDaily. Common osteoporosis drugs linked to 24% lower dementia risk in major study.